Additive value of diffusion-weighted MRI in the I-SPY 2 TRIAL.

ABSTRACT:

Background

The change in apparent diffusion coefficient (ADC) measured from diffusion-weighted imaging (DWI) has been shown to be predictive of pathologic complete response (pCR) for patients with locally invasive breast cancer undergoing neoadjuvant chemotherapy.

Purpose

To investigate the additive value of tumor ADC in a multicenter clinical trial setting.

Study type

Retrospective analysis of multicenter prospective data.

Population

In all, 415 patients who enrolled in the I-SPY 2 TRIAL from 2010 to 2014 were included.

Field strength/sequence

1.5T or 3T MRI system using a fat-suppressed single-shot echo planar imaging sequence with b-values of 0 and 800 s/mm2 for DWI, followed by a T1-weighted sequence for dynamic contrast-enhanced MRI (DCE-MRI) perfor

SUBMITTER: Li W 

PROVIDER: S-EPMC6815231 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature